Clinical Trials Directory

Trials / Unknown

UnknownNCT03292744

Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly

Effect of Alfacalcidol Supplementation to Respiratory Infection, Inflammatory Markers and CD4/CD8 Ratio of Indonesian Elderly

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
110 (estimated)
Sponsor
Indonesia University · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Accepted

Summary

Vitamin D has been known to influence immune response through Vitamin D Receptor in Immune Cells, but only few has been known about the effect alfacalcidol, a vitamin D analog to immune system. In elderly, immune disregulation or immunosenecence have great impact to infection response. This study is aimed to determine the effect of alfacalcidol supplementation in vitro and in vivo to respiratory infection incidence and inflammatory markers, as well as T cell lymphocyte subset in Indonesian elderly patients.

Detailed description

This study consist of 2 designs. First is in vitro study to investigate the effect of alfacalcidol supplementation to IL-6, IL-10 and IFN gamma regulation in Peripheral Blood Mononuclear Cells (PBMC) of elderly and second design is randomised controlled trial to evaluate the effect of 3 months supplementation of alfacalcidol 0,5 mcg in respiratory infection, antibiotic use, inflammatory markers, CD4/CD8 ratio and CD8+ CD28+ in Indonesian elderly with various level of frailty syndrome.

Conditions

Interventions

TypeNameDescription
DRUGAlfacalcidolalfacalcidol 0,5 mcg

Timeline

Start date
2017-01-10
Primary completion
2017-10-10
Completion
2017-12-15
First posted
2017-09-26
Last updated
2017-09-26

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT03292744. Inclusion in this directory is not an endorsement.